Expression of p27(Kip1), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells

International Urology and Nephrology

Volumn 40, Issue 4, 2008, Pages 953-959

  Nikoleishvili, David ^a   Pertia, Ambrosi ^a   Trsintsadze, Omar ^a   Gogokhia, Nino ^b   Managadze, Laurent ^a   Chkhotua, Archil ^a  

^a A Tsulukidze National Centre of Urology   (Georgia)

^b State Medical Academy   (Georgia)

Author keywords

BPH; Cyclin D3; Ki67; p27(Kip1); Prostate cancer

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HORMONE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DOWN REGULATION; EPITHELIUM CELL; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; TISSUE DISTRIBUTION; UPREGULATION; VASCULAR ENDOTHELIUM;

AGED; ANALYSIS OF VARIANCE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DNA DAMAGE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 56249131113     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9350-y     Document Type: Article

References (18)

1. Poulos CK, Daggy JK, Cheng L (2005) Preoperative prediction of Gleason grade in radical prostatectomy specimens: The influence of different Gleason grades from multiple positive biopsy sites. Mod Pathol 18:228-234
2. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
3. Thomas GV, Schrage MI, Rosenfelt L et al (2000) Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 164:1996-1997
4. Faussillon M, Monnier L, Junien C, Jeanpierre C (2005) Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor. Cancer Lett 221:67-75
5. Mirtti T, Kallajoki M, Aaltonen M, Alanen K (2001) Cyclin A and Ki-67 with DNA content in benign and malignant prostatic epithelial lesions. Anal Quant Cytol Histol 23:229-239
6. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA (2001) Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 21:4071-4076
7. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York
8. Chkhotua AB, Gabuzi E, Altimari A et al (2003) Increased expression of p16 (INK4a) and p27 (Kip1) cyclin-dependent kinase inhibitor genes in ageing human kidney and chronic allograft nephropathy. Am J Kidney Dis 41:1303-1313
9. Freedland SJ, de Gregorio F, Sacoolidge JC et al (2003) Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 169:1325-1330
10. Pollack A, DeSilvio M, Khor LY et al (2004) Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation therapy oncology group trial 92-02. J Clin Oncol 22:2133-2140
11. Ojea Calvo A, Mosteiro-Cervino MJ et al (2004) The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy. Actas Urol Esp 28:650-660
12. Kuczyk M, Machtens S, Hradil K et al (1999) Predictive value of decreased P27 Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer J 81:1052-1058
13. Cheng L, Lloyd RV, Weaver AL et al (2000) The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6:1896-1899
14. Zeng L, Rowland RG, Lele SM, Kyprianou N (2004) Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 35:290-297
15. Gandour-Edwards R, Mack PC, deVere-White RW, Gumerlock PH (2004) Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 7:321-326
16. Dreher T, Zentgraf H, Abel U et al (2004) Reduction of PTEN and p27 KIP1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444:509-517
17. Inoue T, Segawa T, Shiraishi T et al (2005) Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66:332-337
18. Zellweger T, Ninck C, Bloch M et al (2005) Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113:619-628